U.K.’s NICE Plans Office To Help Drugs Gain Coverage Faster
NICE is responding to a government consultation on how the cost-effectiveness watchdog should update its methodologies and processes in evaluating new products by opening a new Office for Market Access, which it says will help life sciences companies prepare for its appraisals and better their chances for coverage.
You may also be interested in...
The spread of Ebola to Europe is prompting regulators and industry to explore in more detail adaptive licensing pathways to speed access to potentially life-saving drugs.
The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.
Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.